Chester County News and Community Website
LIMERICK, PA — The Victory Bancorp, Inc. (OTCQX: VTYB), the parent company of The Victory Bank, announced its unaudited financial results for the first quarter ended March 31, 2024, showcasing …
Victory Bancorp Reports Solid Growth and Strong Credit Quality in First Quarter 2024 Read More
NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) reported its financial results for the first quarter of 2024 this week, alongside an update on its business developments that signal a …
Traws Pharma Announces First Quarter Financial Results and Progress in Respiratory and Oncology Programs Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leading dermatology company, reported a decline in first-quarter revenue for 2024 but noted several positive signs of recovery stemming from …
STRATA Skin Sciences Sees Encouraging Signs Amid Strategic Shift, Despite Revenue Dip Read More
CHESTERBROOK, PA — Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company, spotlighted its first-quarter achievements and financial standing, underscoring advancements in its novel treatment for chronic pain and epilepsy and strategic …
Trevena Reports Progress in Pain and Epilepsy Treatment Development, Amid Financial Adjustments Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) this week unveiled promising updates on its clinical trials and financial standing for the first quarter ending March 31, 2024. The company’s …
Cabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future Innovations Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel cancer treatments, reported notable advancements in its first-quarter financial results and clinical trials, including receiving …
Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on gene therapies for eye diseases, reported its first-quarter financial results for 2024 and provided an update on its …
Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) recently shared its first-quarter financials and highlighted recent advancements in its clinical trials. Among the key updates, interim data from its upliFT-D …
Passage Bio Reports Promising Interim Data in FTD-GRN Treatment Trial Read More
YARDLEY, PA — Optinose (NASDAQ: OPTN), a specialty pharmaceutical company, announced its financial results for the first quarter of 2024, showcasing a strong performance with a notable increase in revenue …
Optinose Reports Growth in Q1 and Optimistic Outlook for XHANCE Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) recently disclosed their financial results for the first quarter of 2024, while also providing an update on their business operations. …
Orchestra BioMed Unveils Q1 2024 Financial Results, Advances Pivotal Studies on Innovative Medical Therapies Read More